#### Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.
ARBN	152 854 923

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neville Mitchell
Date of last notice	9 April 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	CHESS Depositary Interests (CDIs) held by N J Mitchell Superannuation Fund (Neville Mitchell has a beneficial interest in the above Fund)	
Date of change	14 May 2021	
No. of securities held prior to change	61,250	Options (unquoted) (OSPAO) with exercise price of A\$0.38 per Share
	50,000	Options (unquoted) (OSPAO) with exercise price of A\$0.26 per Share
	215,000	Options (unquoted) (OSPAO) with exercise price of A\$0.23 per Share
	479,141	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	627,417	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share

<sup>+</sup> See chapter 19 for defined terms.

	Totals:1.432,808Options (unquoted) (OSPAO)(exercisable into an equivalent of 2,865,616 CDIs)3,000,003 CDIs held by N J Mitchell SuperannuationFund(Neville Mitchell has a beneficial interest in the aboveFund)	
Class Issued	Options (unquoted)	
No. of securities issued	1,400,000	
Number of securities disposed/cancelled	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration. Issue of Options to Neville Mitchell was in accordance with the Osprey Medical 2016 Stock Incentive Plan.	
No. of securities held after change	61,250	Options (unquoted) (OSPAO) with exercise price of A\$0.38 per Share
	50,000	Options (unquoted) (OSPAO) with exercise price of A\$0.26 per Share
	215,000	Options (unquoted) (OSPAO) with exercise price of A\$0.23 per Share
	479,141	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	627,417	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	700,000	Options (unquoted) (OSPAO) with exercise price of A\$0.034 per Share

<sup>+</sup> See chapter 19 for defined terms.

	Totals: <u>2,132,808</u> Options (unquoted) (OSPAO) (exercisable into an equivalent of 4,265,616 CDIs) 3,000,003 CDIs held by N J Mitchell Superannuation Fund (Neville Mitchell has a beneficial interest in the above Fund)
Nature of change	Grant of Options pursuant to stockholder approval
Example: on-market trade, off-market trade, exercise of options,	granted at the Annual Meeting of Stockholders
issue of securities under dividend reinvestment plan,	held on 11 May 2021. The exercise price of the
participation in buy-back	Options upon vesting is \$0.34.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above	N/A
traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

<sup>+</sup> See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this	N/A
provided?	

<sup>+</sup> See chapter 19 for defined terms.